“EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis”, J of Skin, vol. 9, no. 6, p. s633, Nov. 2025, doi: 10.25251/jg65bt44.